The response to platinum-taxane chemotherapy in the context of aberrantly activated BRD4 isoform(s) is a highly relevant area of research considering the poor prognosis of ovarian carcinoma patients harboring BRD4 amplification. The gene discussed is BRD4; the disease is ovarian carcinoma.